Consistently, preclinical studies using genetic or antibody-mediated TLR2 blockade (e.g., OPN-301) inhibited tumorigenesis in gastric and pancreatic carcinomas, and head and neck cancers [201]. The gene discussed is SPP1; the disease is head and neck cancer.